{
    "nctId": "NCT02659631",
    "briefTitle": "PF-06671008 Dose Escalation Study in Advanced Solid Tumors",
    "officialTitle": "A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1",
    "eligibilityCriteria": "Key Inclusion Criteria\n\n* Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available\n* Performance status of 0 or 1\n* Adequate bone marrow, kidney and liver function\n\nKey Exclusion Criteria\n\n* Known CNS disease including, but not limited to, metastases\n* Current or history of seizure disorder\n* History of or active autoimmune disorders\n* Active bacterial, fungal or viral infection\n* Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment\n* Requirement for systemic immune suppressive medication\n* Grade 2 or greater peripheral neuropathy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}